Invasive Group B Streptococcus Disease With Recurrence and in Multiples: Towards a Better Understanding of GBS Late-Onset Sepsis

Mirjam Freudenhammer1,2,3†, Konstantinos Karampatsas4†, Kirsty Le Doare4, Fabian Lander5, Jakob Armann5, Daniel Acero Moreno6, Margaret Boyle7, Horst Buxmann8, Ruth Campbell9, Victoria Chalker10, Robert Cunney11,12, Lorraine Doherty9, Eleni Davies13, Androulla Efstratiou14, Roland Elling1,2, Matthias Endmann15, Jochen Essers16, Roland Hentschel2, Christine E. Jones17, Steffen Kallsen16, Georgina Kapatai10, Marcus Krüger19, Sharmeen Ladhani4,20, Theresa Lamagni14, Diane Lindsay21, Mary Meehan12, Catherine P. O’Sullivan4, Darshana Patel1,4, Arlene J. Reynolds22, Claudia Roll23, Sven Schulze24, Andrew Smith21,25, Anja Stein26, Axel von der Wense27, Egbert Voss28, Christian Wieg29, Christoph Härtel30,31, Paul T. Heath4* and Philipp Henneke1,2,3,31*

1 Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 2 Center for Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 3 IMM-PACT Clinician Scientist Programme, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 4 Paediatric Infectious Diseases Research Group, Institute of Infection and Immunity, St. George’s, University of London, London, United Kingdom, 5 Department of Pediatrics, University Hospital and Medical Faculty Carl Gustav Carus, Technische Universität (TU) Dresden, Dresden, Germany, 6 Department of Neonatology, Kinderkrankenhaus Amsterdamer Straße, Cologne, Germany, 7 Department of Health Northern Ireland, Belfast, United Kingdom, 8 Department of Paediatric and Adolescent Medicine, Division for Neonatology at the University Hospital Frankfurt, Frankfurt/Main, Germany, 9 Public Health Agency Northern Ireland, Belfast, United Kingdom, 10 Immunisation, Hepatitis and Blood Safety Department, Public Health England, London, United Kingdom, 11 Health Service Executive, Health Protection Surveillance Centre, Dublin, Ireland, 12 Irish Meningitis and Sepsis Reference Laboratory, Temple Street Children’s University Hospital, Dublin, Ireland, 13 Public Health Wales, Cardiff, United Kingdom, 14 National Infection Service, Public Health England, London, United Kingdom, 15 Department of Paediatric and Adolescent Medicine, St. Franziskus Hospital Ahlen, Ahlen, Germany, 16 Department of Paediatrics, University of Ulm, Ulm, Germany, 17 Faculty of Medicine and Institute for Life Sciences, University of Southampton and NHR Southampton Clinical Research Facility and NHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, 18 Department of Paediatrics and Youth Medicine, Klinikum Friedrichsfelden, Friedrichsfelden, Germany, 19 Department of Neonatology, München Klinik Harlaching and Schwabing, Munich, Germany, 20 Immunisation and Countermeasures Division, Public Health England, London, United Kingdom, 21 Scottish Microbiology Reference Laboratory, Glasgow Royal Infirmary, Glasgow, United Kingdom, 22 Health Protection Scotland, Glasgow, United Kingdom, 23 Department of Neonatology, Vast Children’s Hospital Datteln, University Witten-Heerde, Witten-Heerde, Germany, 24 Department of Neonatology, University Children’s Hospital Basel UKBB, Basel, Switzerland, 25 Glasgow Dental Hospital and School, University of Glasgow, Glasgow, United Kingdom, 26 Department of Pediatrics, University Hospital Essen, University Duisburg-Essen, Essen, Germany, 27 Neonatology and Pediatric Intensive Care, Altonaer Children’s Hospital, Altonaer Kinderkrankenhaus, Hamburg, Germany, 28 Klinik Hallenwiese-Capfische Kinderklinik, Nürnberg, Germany, 29 Department of Neonatology, Klinikum Aschaffenburg, Aschaffenburg, Germany, 30 Department of Pediatrics, University of Würzburg, Würzburg, Germany, 31 PRIMAL (Priming Immunity at the Beginning of Life) Consortium, Freiburg/Lübeck, Germany.
INTRODUCTION

Group B streptococcus (GBS) is a leading cause of sepsis and meningitis in young infants worldwide (1). Globally in 2015, over 300,000 cases of invasive GBS disease (iGBS) caused 90,000 deaths in infants <90 days of age (2) and neurodevelopmental impairment in over 10,000 children (3). IGBS is divided into early-onset sepsis (EOS), with disease onset – depending on the definition – either in the first 3 or 6 days, and late-onset sepsis (LOS) occurring thereafter and before day 90. Maternal GBS colonization can lead to EOS via vertical transmission at or before birth through ruptured membranes (4). Many countries have reported a reduction in the incidence of EOS after introducing administration of intrapartum intravenous antibiotics (IAP) to women at risk of transmitting GBS to their newborns (5, 6).

In contrast, the understanding of transmission and risk factors for LOS is still incomplete. Prematurity and maternal colonization increase the risk of LOS (7). In healthy infants, mother to infant transmission of GBS can continue for weeks after delivery (8). Neonatal colonization patterns matter, since colonization may precede invasive infection (9).

The host-microbiome interactions are highly dynamic in the first months of life (10). IAP has been shown to alter the composition of the infant gut microbiota (11–13). It is therefore conceivable that early distortions of the host-commensal adaptation, mediated by perinatal antibiotic exposure, may contribute to the pathogenesis of LOS. Indeed, several studies have reported an increase in GBS LOS after implementation of IAP, although this remains a controversial issue (14–16).

Two particularly instructive entities of iGBS are those occurring in infants of multiple births and those with recurrent episodes. The increased risk of multiple pregnancies for preterm delivery and adverse outcomes in general is well established (17), yet uncertainty exists about the specific association with iGBS. In part due to the lack in understanding of disease pathogenesis, there is no consensus about the management of the asymptomatic sibling of an iGBS case from a multiple birth (18). Additionally, the mechanisms underlying recurrent disease are not fully understood. Prematurity, persistent mucosal colonization and contaminated breast milk have been proposed as risk factors (19). Since the shared (multiples) or fixed (recurrence) genetic and environmental conditions may shed some light on iGBS pathogenesis, this study analyzed cases in multiples or with recurrence. From this analysis and review of published GBS cases, we derive a model for LOS pathogenesis to identify the infant at risk.

METHODS

Study Design
UK and Ireland: Enhanced national surveillance of iGBS in infants under three months of age in the UK and Republic of Ireland (UKROI) was conducted between April 1, 2014, and April 30, 2015. Data were collected through the British Paediatric Surveillance Unit together with laboratories in England, Wales, Scotland, Northern Ireland and Ireland. Serotyping using latex agglutination and multilocus sequence typing (MLST) was performed by Public Health England and the Irish Meningitis and Sepsis Reference Laboratory. The study was approved by the South East Coast – Brighton and Sussex Research Ethics Committee (REC reference: 13/LO/1912; IRAS Project ID: 137959). The detailed methodology has been published (20).
Analyses were performed using STATA and R software. After removing all the cases that died after the associations with recurrent GBS infections in the UKROI cohort, groups. A univariable regression analysis was used to estimate used to compare continuous and categorical variables between using penalized regression to alleviate problems of accuracy after concomitant onsets. The narrow EOS definition was chosen, since > 90% of cases in the first week of life occur in this time frame. One episode of culture negative sepsis was included because it was highly suggestive of GBS LOS (clinical sepsis with consistent laboratory abnormalities, isolation of GBS from infant’s oropharynx, a concurrent episode of culture-positive GBS sepsis in the sibling and subsequent culture-positive relapse of iGBS).

Index case: The first infant among multiples with iGBS.

Recurrent iGBS: New episode of clinical illness in an infant associated with the isolation of GBS from a sterile site occurring after the completion of the therapy for the first occurrence.

GBS colonization in infants: Positive oropharyngeal, ear or rectal swab or gastric aspirate by culture or PCR.

Interval between two recurrent iGBS episodes: Days between completion of antibiotics and onset of subsequent iGBS.

Duration of antibiotic treatment: Duration of the antibiotic treatment of iGBS (penicillins or third generation cephalosporins).

Short course of antibiotic treatment: Treatment <10 days (21).

Statistical Analysis
Continuous variables were presented as median and range and categorical data as numbers and percentages. Student’s t test or the Mann–Whitney U test and x2 test or Fisher’s exact test were used to compare continuous and categorical variables between groups. A univariable regression analysis was used to estimate associations with recurrent GBS infections in the UKROI cohort, after removing all the cases that died after the first GBS episode. Missing data were removed from the analysis. P value < 0.05 was considered significant. A multivariable model was produced using penalized regression to alleviate problems of accuracy associated with the small size of the database. Akaike’s Information Criteria (AIC) were used for model selection. Analyses were performed using STATA and R software.

Literature Review of Cases With iGBS Recurrence
Medline and Embase were searched via Ovid from 1974 - 03/ 2020 for terms “Streptococcus agalactiae”, “group B strep”, “strep* agala*”, “GBS”, “double or recur” or episodes or relaps* or consecutive* or twice or two or three or four or five or repet*”, “Infant, Newborn/n”, “newborn*”, “neonat*”, “infant* adj4 (week* or day* or month* or premature or full term or postmature or preterm). Additional studies were identified in references of articles. Two cases in the current case study were previously reported and excluded from the review (22, 23).

RESULTS
GBS in Infants From Multiple Births
UKROI Cohort
Demographic and Clinical Characteristics
A total of 41 iGBS cases in infants from 35 multiple birth pregnancies were identified, including six infant pairs in which both twins developed iGBS (17%) (Table 1A). Twelve infants from ten twin pairs had EOS, of which in two twin pairs (20%) both infants developed EOS. The median gestational age (GA) of twins with one sibling affected by GBS EOS was 35 (range 23-38) weeks. LOS was diagnosed in 29 infants from 25 twin pairs, of which in four twin pairs (16%) both infants developed iGBS. Based on a LOS incidence of 0.37 per 1000 live births in this population (20), the risk for LOS in a child from a multiple gestation with an already affected sibling was over 400 times higher. Comparison of the multiples with one versus two affected infants revealed no significant differences in GA (median 32 weeks for both groups) or birth weight (median 1620 (860-3560) g vs. 1685 (1070-2810) g). Median age at onset of GBS LOS was 42 (7-86) days if one, and 27 (4-54) days, if two infants were affected. The median interval in onset of disease between siblings was 2.5 (0-18) days.

GBS sero- and sequence-typing revealed serotype III/ST-17 in all three tested twin sets with both infants affected by LOS and in 5/12 (42%) isolates from twin cases with only one infant affected, the rest accounted for serotypes III/ST-19 (n=2), Ia/ST-23 (n=4) and VI/ST 17 (n=1). The median treatment duration was 14 (7-32) days for sepsis and 14.5 (14-21) days for meningitis.

Demographic and Clinical Characteristics
Twins had a lower birth weight (median 1828 vs 3230 g, P < 0.001) were more often born prematurely (85% vs 24%, P < 0.001), and developed iGBS significantly later (median 25 days vs 1 day, P < 0.001) than singletons (Table S1). The relapse rate was similar (2.4% vs 1.7%, P = 0.5).

Demographic and Clinical Characteristics
Data on the management of the asymptomatic twin sibling of an index case were available for 12 twin pairs. Eight infants were clinically evaluated and antibiotics were not started, two of these developed iGBS. In four cases antibiotic treatment was preemptively administered to the second twin and stopped after confirmation of negative cultures.

German/Swiss Cohort
Demographic and Clinical Characteristics
Seven sets of twins and two sets of triplets, a total of 20 infants, with GBS LOS were identified (Table 1B). One twin set showed iGBS recurrence in both infants, leading to a total of 22 LOS episodes in these multiples. All infants were born prematurely, the median GA at birth was 31 (25-36) weeks. 7/20 infants (35%) were low birth weight (<2500 g, LBW) and 13/20 (65%) very low birth weight (<1500 g, VLBW). 11 (55%) infants were male. 4/9 pregnancies were di/trizygotic, 1/9 monozygotic, 2/9 were identified as dichorionic/diamniotic, for two pregnancies the information was lacking.

Germany and Switzerland: Medical centers from the German Neonatal Network (GNM), consisting of 65 sites, were asked for GBS LOS cases from 2008-2020 with a recurrent course or with more than one affected multiple. This was complemented by an e-mail request to 120 additional medical centers with NICUs in Germany and Switzerland. Data were collected via data entry forms. Data collection was approved by the ethics committee of Freiburg University (Nr. 207/20).
**TABLE 1A** | Clinical features of GBS infections in infants from multiple births (UKROI).

| Patient ID | gestational age (w) | Sex | birth weight (g) | Chorioamnionitis | Delivery mode | ATX labour/ birth | GBS maternal swab | ATX age at LOS onset (d) | Signs and symptoms | GBS detection | GBS LOS episode | ATX (d) | Management of other twin | recurrence |
|------------|---------------------|-----|-----------------|-------------------|---------------|------------------|------------------|------------------------|-------------------|-------------|-----------------|---------|------------------------|-----------|
| EOS - only one sibling with iGBS | | | | | | | | | | | | | | |
| 1 | 35 | M | 2650 | N | V | neg | N | 0 | P | B | N/A | N/A | 21 | N/A |
| 2 | 23 | M | 610 | Y | V | N/A | N | 1 | S | B | N/A | N/A | 14 | N/A |
| 3 | 38 | M | 3425 | N | V | neg | N | 1 | P | B | III | 17 | 14 | N/A |
| 4 | 36 | M | 2030 | N | V | neg | N | 3 | M | B/CSF | III | 17 | 14 | N/A |
| 5 | 39 | M | 2700 | N | V | pos | N | 0 | S | B | N/A | N/A | 7 | N/A |
| 6 | 36 | F | 2110 | Y | CS | neg | N | 0 | S | B | N/A | N/A | 7 | N/A |
| 7 | 33 | M | 1875 | Y | CS | neg | N | 0 | S | B | V | 1 | N/A | N/A |
| 8 | 35 | F | 2272 | N | V | neg | N | 1 | S | B | N/A | N/A | 7 | N/A |
| EOS - all siblings with iGBS | | | | | | | | | | | | | | |
| 9a | 36 | M | N/A | N | V | neg | N | 1 | S | B | III | NA | 14 | SM |
| 9b | 36 | M | F | 1760 | N | CS | neg | Y | 0 | S | B | N/A | N/A | 7 | SM |
| 10a | 33 | F | 2305 | N | N | neg | N | 1 | M | B/CSF | III | 17 | 21 | SM |
| 10b | 33 | M | 1870 | N | Cs | neg | N | 0 | M | B/CSF | N/A | N/A | 14 | SM |
| LOS - only one sibling with iGBS | | | | | | | | | | | | | | |
| 11 | 26 | M | 1060 | N/A | N/A | N/A | N/A | 80 | S | B | III | 19 | 10 | CE |
| 12 | 37 | M | 3140 | N/A | N/A | N/A | N/A | 53 | S | B | N/A | N/A | 10 | CE |
| 13 | 34 | M | 2040 | N/A | N/A | N/A | N/A | 42 | S | B | III | 19 | N/A | CE |
| 14 | 30 | F | 1440 | N/A | N/A | N/A | N/A | 85 | S | B | N/A | N/A | N/A | N/A |
| 15 | 32 | M | 1550 | N/A | N/A | N/A | N/A | 72 | S | B | N/A | N/A | 14 | N/A |
| 16 | 26 | M | 940 | N/A | N/A | N/A | N/A | 49 | S | B | VI | 17 | N/A | N/A |
| 17 | 34 | F | 2150 | N/A | N/A | N/A | N/A | 31 | M | B/CSF | III | 17 | 21 | N/A |
| 18 | 34 | F | 1690 | N/A | N/A | N/A | N/A | 35 | S | B | N/A | N/A | 28 | N/A |
| 19 | 36 | F | 2305 | N/A | N/A | N/A | N/A | 7 | M | B/CSF | la | 23 | 14 | N/A |
| 20 | 32 | M | 1150 | N/A | N/A | N/A | N/A | 21 | S | B | N/A | N/A | 14 | pA |
| 21 | 37 | F | 2780 | N/A | N/A | N/A | N/A | 52 | M | B/CSF | III | 17 | 21 | CE |
| 22 | 36 | F | 1785 | N/A | N/A | N/A | N/A | 86 | S | B | N/A | N/A | 14 | N/A |
| 23 | 25 | M | 860 | N/A | N/A | N/A | N/A | 46 | S | B | N/A | N/A | 15 | N/A |
| 24 | 38 | F | 1440 | N/A | N/A | N/A | N/A | 70 | S | B | N/A | N/A | 32 | N/A |
| 25 | 28 | F | 1115 | N/A | N/A | N/A | N/A | 20 | S | B | III | 17 | 14 | N/A |
| 26 | 32 | M | 1940 | N/A | N/A | N/A | N/A | 42 | S | B | la | 23 | 7 | N/A |
| 27 | 35 | F | 2305 | N/A | N/A | N/A | N/A | 35 | S | B | III | 17 | 21 | CE |
| 28 | 34 | M | 2360 | N/A | N/A | N/A | N/A | 32 | M | B/CSF | III | 17 | 15 | pA |
| 29 | 27 | F | 890 | N/A | N/A | N/A | N/A | 66 | M | B/CSF | la | 23 | 14 | N/A |
| 30 | 30 | F | 1450 | N/A | N/A | N/A | N/A | 17 | S | B | la | 23 | 8 | CE |
| 31 | 29 | F | 1095 | N/A | N/A | N/A | N/A | 25 | M | B/CSF | N/A | N/A | 21 | pA |
| LOS - all siblings with iGBS | | | | | | | | | | | | | | |
| 32a | 38 | F | 2620 | N | CS | neg | N | 5 | S | B | III | 17 | 10 | NpA |
| 32b | 38 | M | 2910 | N | CS | neg | N | 4 | M | B/CSF | III | 17 | 14 | NpA |
| 33a | 32 | M | 1750 | N/A | N/A | N/A | N/A | 31 | M | B/CSF | III | 17 | 14 | N/A |
| 33b | 32 | M | 2005 | N/A | N/A | N/A | N/A | 13 | S | B | III | 17 | 14 | N/A |
| 34a | 30 | M | 1620 | N/A | N/A | N/A | N/A | 50 | S | B | III | 17 | 21 | N/A |
| 34b | 30 | M | 1070 | N/A | N/A | N/A | N/A | 54 | M | B/CSF | III | 17 | 21 | N/A |
| 35a | 33 | F | 1520 | N/A | N/A | N/A | N/A | 30 | S | B | N/A | N/A | 14 | NpA |
| 35b | 33 | F | 1350 | N/A | N/A | N/A | N/A | 24 | S | B | N/A | N/A | 14 | NpA |

ABX, antibiotics; B, Blood; CE, clinical evaluation; CS, caesarean section; CSF, cerebrospinal fluid; S, sepsis; M, meningitis; NpA, no prophylactic ABX; P, pneumonia; pA: prophylactic ABX administered pending the results of bacterial cultures, SM Simultaneous occurrence of GBS infection; V vaginal delivery.

*Infants from the same family are indicated with the same number plus a,b,c.*
### TABLE 1B | Clinical features of GBS infections in infants from multiple births (German/Swiss cohort).

| Birth | GBS | ATX | LOS | Recurrence |
|-------|-----|-----|-----|------------|
| Sex   |     |     |     |            |
| Chorioamnionitis |   |     |     |            |
| Delivery |   |     |     |            |
| ATX-indication |   |     |     |            |
| age at LOS |   |     |     |            |
| LOS after |   |     |     |            |
| LOS-affected |   |     |     |            |
| LOS outcomes |   |     |     |            |
| LOS-affected |   |     |     |            |
| LOS indications |   |     |     |            |

#### Demographic and Clinical Characteristics

| Infant ID | Birth | GBS | ATX | LOS | Recurrence |
|-----------|-------|-----|-----|-----|------------|
|           |       |     |     |     |            |
|           |       |     |     |     |            |
|           |       |     |     |     |            |
|           |       |     |     |     |            |
|           |       |     |     |     |            |
|           |       |     |     |     |            |
|           |       |     |     |     |            |
|           |       |     |     |     |            |
|           |       |     |     |     |            |
|           |       |     |     |     |            |

**AA, acute abdomen; ATX, antibiotics; B, Blood; Cl, cellulitis; CS, caesarean section; CSF, cerebrospinal fluid; DC, dichorionic; DZ, dizygotic; G, good; HM, home; HS, hospital; L/C, laparotomy + colostoma; Me, meningitis; N/A, not available; NS, neurologic sequelae; PR, PROM; R, recommended; SP, Section Prophylaxis; S, sepsis; V, vaginal delivery.* sterilization.

**Infants from the same family are indicated with the same number plus a, b, c.

**Increased risk of GBS recurrence (1.9-22.0), P = 0.001**

**Risk factors for GBS Recurrence**

#### Recurrent GBS Disease

**Demographic and Clinical Characteristics**

Twelve cases of recurrent GBS were identified, accounting for 21% of all infants with GBS reported that year (20). There were 5 (5.5%) infants from a twin birth and 7 (7.5%) from a single birth. The median age at onset of first GBS LOS was 48 (11-118) days. The median age at onset of first GBS LOS was 5.5 (1-18) days. GBS grew in blood culture in 20 (91%), and five (23%) cases. Serotyping was performed in 4 (21%) cases. Serotyping was performed in 3 (12%) cases. Serotyping was performed in 2 (9%) cases. Serotyping was performed in 1 (5%) case.

**Appendix S2**
multivariate penalized logistic regression model, the association of GBS recurrence with VLBW [OR 9.7 (2.8-33.3), P < 0.001] and a short course of antibiotics [OR 4.2 (1.3-14.2), P = 0.02] remained significant (Tables 3 and S2).

**German/Swiss Case Series**

**Demographic and Clinical Characteristics**

Thirteen cases of recurrent iGBS were reported from ten centers in Germany and Switzerland within a 12-year period (Table 2). Nine (69%) infants were born prematurely (median 32, range 23-41 weeks) and six (46%) were VLBW. Nine (69%) infants were born prematurely (median 32, range 23-41 weeks). The median age at the onset of the first iGBS was 28 (1-150) days. Three (23%) infants had EOS. GBS was isolated in the blood culture in all 13 cases. Three out of nine cases with a lumbar puncture had a concurrent meningitis. The first episode was treated with antibiotics for 14 (7-21) days. Recurrence of iGBS occurred at a median age of 44 (24-64) days. The median interval from completion of initial therapy to onset of second episode was nine (3-37) days. In three cases (25%) GBS grew in the CSF culture in the second episode in addition to the blood culture. The median duration of antibiotic therapy for the second episode was 14 (9-19) days. GBS capsular serotyping was performed in one (8%) case (serotype III ST-17). Breast milk samples from eight (62%) out of 13 tested breastfeeding women revealed a positive result (by culture or PCR) in five women during the first or second episode. In six (50%) out of 12 cases, where data were reported, breastfeeding was stopped after the first or second iGBS episode and restarted after antibiotics for GBS “eradication” in two of these six cases. In one further case breast milk was pasteurized.

Four infants were treated with antibiotics with the aim to decrease GBS colonization or prevent further bacterial infections until immunological investigations were completed. In nine infants, where immunological tests were done, two were diagnosed with transient hypogammaglobulinemia, one had

| Table 2 | Clinical features of cases of recurrent GBS disease. |
|---------|-----------------------------------------------|
| Country | ID  | Sex | BW (g) | GA (w) | DM | 1st episode | 2nd episode | 3rd episode | Isolates | Colonisation | Breast milk | Outcome          |
|---------|-----|-----|--------|--------|----|-------------|-------------|-------------|----------|-------------|------------|-----------------|
| Germany | 1   | F   | 565    | 23     | CS | 1 B 10      | 48 B 12     | 124 B 21    | N/A      | N/A         | pos        | neg Yes         |
| Germany | 2   | F   | 670    | 25     | CS | 41 B 14     | 84 B 21     | –          | –        | –           | –          | pos No*         |
| Germany | 3   | F   | 1230   | 27     | V  | 46 B 7      | 62 B 10     | –          | –        | –           | –          | neg pos         |
| Germany | 4   | F   | 590    | 23     | N/A| 150 B 9     | 166 B/14    | –          | –        | –           | –          | neg pos         |
| Germany | 5   | F   | 1732   | 32     | CS | 35 B 14     | 64 B 14     | –          | –        | –           | –          | neg pos         |
| Germany | 6   | F   | 1470   | 32     | CS | 28 B/14     | 63 B 14     | –          | –        | –           | –          | neg pos         |
| Germany | 7   | F   | 2890   | 39     | V  | 10 B 10     | 25 B 14     | –          | –        | –           | –          | neg pos         |
| Germany | 8   | F   | 4320   | 37     | V  | 1 B 15      | 25 B 14     | –          | –        | –           | –          | pos N/A         |
| Germany | 9   | M   | 3020   | 37     | CS | 1 B 14      | 21 B 14     | –          | –        | –           | –          | pos N/A         |
| Germany | 10  | M   | 3020   | 35     | V  | 20 B/15     | 60 B 14     | –          | –        | –           | –          | pos N/A         |
| Germany | 11  | F   | 4190   | 41     | V  | 3 B 7       | 24 B 14     | –          | –        | –           | –          | neg N/A         |
| Germany | 12  | F   | 1125   | 28     | CS | 48 B/19     | 94 B 19     | –          | –        | –           | –          | neg pos         |
| Germany | 13  | N/A | 1920   | 31     | CS | 47 B 10     | 60 B 9      | –          | –        | –           | –          | neg N/A         |
| UKROI  | 14  | F   | 1082   | 27     | N/A| 39 B 10     | 59 B 14     | –          | –        | –           | –          | neg No**        |
| UKROI  | 15  | M   | 3770   | 39     | V  | 0 B 7       | 23 B 14     | –          | –        | –           | –          | neg N/A         |
| UKROI  | 16  | M   | 3350   | 42     | N/A| 11 B 7      | 25 B 14     | –          | –        | –           | –          | neg N/A         |
| UKROI  | 17  | M   | 2020   | 31     | N/A| 73 B 5      | 84 B 42     | –          | –        | –           | –          | neg N/A         |
| UKROI  | 18  | M   | 770    | 23     | N/A| 1 B 9       | 30 B/21     | –          | –        | –           | –          | neg N/A         |
| UKROI  | 19  | M   | 1070   | 30     | V  | 26 B/CS     | 54 B/21     | –          | –        | –           | –          | pos V/III       |
| UKROI  | 20  | M   | 1490   | 29     | N/A| 37 B 10     | 59 B/CS     | –          | –        | –           | –          | neg III         |
| UKROI  | 21  | M   | 3150   | 40     | N/A| 11 B 7      | 38 B/21     | –          | –        | –           | –          | neg III         |
| UKROI  | 22  | M   | 3900   | 41     | N/A| 16 B 7      | 28 B 14     | –          | –        | –           | –          | neg III         |
| UKROI  | 23  | M   | 600    | 23     | N/A| 0 B 7       | 82 B/CS     | –          | –        | –           | –          | neg III         |
| UKROI  | 24  | M   | 1620   | 31     | N/A| 8 B 14      | 41 B 14     | 69 B 14    | III       | 23          | N/A         | N/A             |
| UKROI  | 25  | F   | 1790   | 32     | N/A| 0 B 10      | 23 B/CS     | –          | –        | –           | –          | neg V/CS        |

*AN: Abnormal; C: Cellulitis; CS: Cesarean section; D: Death; DD: Developmental delay; Imm: Immunology; Me: Meningitis; N: Normal; N/A: Not available; S: Sepsis; Seq.: Sequelae; V: Vaginal delivery; *Pasteurized; **Temporary (restarted after maternal decolonization); ^: lack of Memory B cells and neutropenia; ^^: transient hypogammaglobulinemia; ^^^: reduced CH50 activity (<10%).
TABLE 3 | Univariable and Multivariable Logistic Regression analysis of recurrent GBS disease (UKROI).

| Variable                        | Univariable | Multivariable |
|---------------------------------|-------------|---------------|
|                                | OR (95% CI) | P value       | OR (95% CI) | P value       |
| Antibiotic course <10 d         | 3.2 (1.0-10.9) | 0.04 | 4.2 (1.3-18.0) | 0.02 |
| Very Low Birth Weight (<1500 g) | 6.8 (1.9-22.0) | 0.001 | 9.7 (2.8-33.3) | <0.001 |
| Preterm Birth (<37 weeks)       | 5.6 (1.7-21.4) | 0.005 | 3.7 (0.9-15.1) | 0.06 |
| Male Sex                        | 4.4 (1.1-28.7) | 0.05 |                |      |

TABLE 4 | Summary of iGBS cases with recurrence and iGBS in multiples.

| Multiplesb | Gestational age in weeks, median (IQR) | Birth weight g, median (IQR) | Age at onset of 1st iGBS in days, median (IQR) | Infants with ATX before onset of 1st iGBS in % | Interval between iGBS episodes in days, median (IQR)a |
|------------|----------------------------------------|-------------------------------|-----------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| UKROI (n=12) | 32 (5) | 1495 (721) | 33 (40)c | NA | 4.5 (6.5) |
| German/Swiss (n=20) | 33 (4) | 1755 (426) | 27 (25)c | NA | 2.5 (5) |
| Recurrence | 31 (10) | 1220 (742.5) | 48 (58)c | 62.5c | 5.5 (6) |
| UKROI (n=12) | 31 (11) | 1732 (1938) | 35 (30)c | NA | 12.5 (12) |
| German/Swiss (n=13) | 32 (10) | 1705 (2121) | 21 (26.5)c | NA | 13 (11) |

aMultiples: Interval between siblings developing iGBS. Recurrence: Interval between completion of antibiotics for the first iGBS and onset of second iGBS for the same infant.

bMultiple sets >1 sibling affected by iGBS.

reduced complement activity, and one had absent memory B cells and neutropenia.

Literature Review on Recurrent iGBS

Demographic and Clinical Characteristics

We identified 44 case reports or case series of GBS recurrence in 84 infants between 1976 and 2019 (Table S1). Fourteen infants (24%) were twins or triplets. 64 infants (76%) had bacteremia, 16 (19%) had meningitis with bacteremia, three (4%) only meningitis and six infants (7%) had cellulitis (5 with a positive blood culture). The median age at onset of the first episode was 15 (0-120) days. Antibiotics were administered for 10 (7-28) days for the initial episode. Of the infants, in whom information was available 42/74 (57%) were preterm, 30/50 (60%) were males, 28/42 (67%) were born vaginally.

Recurrence of GBS disease occurred at a median age of 40 (8-141) days. The median interval from completion of antibiotic therapy to onset of second episode was eight (0-54) days. 64 infants (76%) had recurrent bacteremia, 16 (19%) had meningitis with bacteremia, and three (4%) meningitis without bacteremia. Antimicrobial therapy for the second episode of iGBS was administered for 14 (10-42) days. A third episode of GBS disease occurred in 11 infants (13%) at a median age of 61.5 (32-141) days. The median interval from completion of antibiotic therapy to onset of second episode was eight (0-54) days. 64 infants (76%) had recurrent bacteremia, 16 (19%) had meningitis with bacteremia, three (4%) only meningitis without bacteremia. Further investigations revealed transient hypogammaglobulinemia in three infants.

Comparison of the Three Cohorts With Recurrence

Recurrent iGBS cases from the UKROI, German/Swiss and literature cohort were largely similar (Figure S1). Fewer infants from the German/Swiss case series were male as compared to UKROI (25% vs 83%, P = 0.01) and the literature (25% vs 60%, P = 0.05). Antibiotic treatment for the first episode of iGBS was shorter in UKROI (median 7 vs 14 days in German/Swiss cases, P = 0.01; vs 12.5 days in literature, P < 0.001). Yet, antibiotic treatment for the second episode of iGBS was longer in UKROI (median 21 vs 14 days in German/Swiss cases, P = 0.002; vs 14 days in literature, P = 0.06). Meningitis in the second GBS episode was more common in UKROI compared to literature (42% vs 13%, P = 0.03).

Summary of Recurrent Cases and iGBS in Multiples

Combining the UKROI and German/Swiss cohorts reveals that infants with recurrent GBS did not differ from multiples, in which more than one sibling developed iGBS with respect to gestational age, birth weight and age of LOS onset (Table 4).

DISCUSSION

Cases of iGBS in infants of multiple births and those with recurrence provide intriguing insights as to how a highly virulent bacterial species adapts, or fails to do so, to the individual mucocutaneous interface as well as to the intra-familial host-commensal community. Birth constitutes a major microbial seeding event. Subsequently, a highly dynamic network develops,
where microorganisms as well as immunologically important macromolecules are exchanged between family members. This goes in parallel with neonatal immune development. Normally, GBS reaches its niche without health implications for its infant host. Up to 20% healthy infants are colonized with GBS at two months of age (8) and iGBS occurs in less than 1% of colonized infants. Recurrence rate is low [1.5% in our cohort in keeping with previous reports (24)], suggesting that iGBS is usually a “singular accident” rather than the result of immune problems in handling this organism. In contrast, it might lead to acquisition of host resistance, since further GBS contacts via the individual flora or family members are likely to occur and in general remain without consequences.

Our study elucidates what might go wrong in this process. In multiples, a sibling with iGBS is a major risk factor, increasing the incidence of iGBS in the other sibling to 17%, i.e. tenfold higher as compared to the risk attributed to maternal colonization (25). The mechanisms of GBS transmission in LOS are still unclear. The main hypotheses are that acute transmission occurs after exposure to a high bacterial load (e.g. via breast milk) and endogenous translocation following mucosal colonization (Figure 1). Our data provide evidence supporting both scenarios. Simultaneous onset of iGBS in siblings within 48 hours, occurring many weeks after birth, is highly suggestive of an acute infection of both siblings from an external source, e.g. the mother. Alternatively, the infecting GBS clone may have changed its phenotype from “colonizing” to “invasive” and may be acutely transferred from one infant to the other, e.g. via the maternal breast. On the other hand, a long interval of up to 18 days in LOS onset between twin siblings suggests fluctuations in the individual host immunity rather than an acute infection.

Prematurity is characterized by disturbances of microbiome development, associated with frequent use of antibiotics, formula feeding and reduced contact with the maternal microbiome. It is tempting to speculate that these factors might disturb the adaptation of GBS to its neonatal host environment. Overall, maternal and subsequent neonatal GBS colonization are major risk factors for iGBS (7). Notably, in the German/Swiss multiple study, maternal antenatal rectovaginal swabs (if available) were all negative for GBS. Nearly all these women received antibiotics prior to birth, which probably reduced short term colonization with GBS, but also caused alterations of infant intestinal composition, such as a reduction in Bifidobacteria or an increase of Firmicutes species (12, 13). Accordingly, “natural” exposure to the adapted maternal GBS strain may have been missing in these infants very early in life. Moreover, antibiotics may alter bacterial virulence, which is best exemplified by the emergence of the hypervirulent GBS type III ST17 clone under tetracycline treatment pressure (26). According to a model where high GBS virulence promotes recurrence and parallel infections in multiples, ST-17 was, when molecular typing was performed, the most common clone isolated in our cohorts. The perinatal use of antibiotics may also directly disturb the development of host immunity, since antibiotics impact on neonatal myeloid cell homeostasis that provides resistance against sepsis (27). The observation that increased use of intrapartum antibiotics lowers the incidence of EOS, but may increase that of LOS is in concordance with this notion (14–16).

**FIGURE 1** | Model of pathogenesis of (recurrent) Group B streptococcus late-onset disease. Several factors (boxes) impact on the outcome of postnatal contact of the neonate with GBS: uneventful integration into microbiome vs. invasive GBS infection (Figure was created using BioRender.com).
Invasive infections with potential pathogens like GBS with recurrence and in siblings are compatible with inherited immune aberrations. However, iGBS is usually a sporadic event and rarely uncovers genetic immunodeficiency (10, 28). Moreover, monozygosity did not stand out as a risk factor in our collection or previous reports (29). However, preterm birth is associated with various alterations of host resistance, e.g. low transplacental antibody transfer (30). Yet, immune functions do not develop in a linear fashion postnatally. For example, immune monocyte and T-cell activation is partly higher, but neutrophil function is impaired in preterm as compared to term infants and adults (31). Occasionally associated hypogammaglobulinemia, complement deficiency and neutropenia often reflect transient alterations rather than inborn errors of immunity.

Breast milk contributes to the protection against infections in various ways (32), but it is also a potential source of infection (33). GBS strains detected in breast milk were of the same serotype as the invasive strains isolated in the infants in our cohort, in case information was available. An alternative hypothesis is that mammary ducts become colonized by contact with the oral mucosa of the infant and GBS in the breast milk may just be a biomarker of the “family microbiome” (19). In general, GBS can persist at mucosal surfaces, and thus as a GBS source, even after adequate parenteral therapy (34). This concurs with the observation that the second episode is typically caused by the same serotype as the first, although this information was not available for all cases. Yet repeated translocation from the natural ecological habitat to the blood stream must be discriminated from failed eradication of truly infective foci by insufficient antibiotic treatment. Thus, the association between shorter antibiotic treatments course and increased recurrence risk, and recurrences within a week after treatment in a third of infants may highlight a subgroup of insufficiently treated cases rather than being paradigmatic for recurrence. The proportion of infants with recurrent iGBS disease that received a short course of antibiotics was disproportionately high in UKROI compared to the German/Swiss case series and the existing literature (Figure S1). Moreover, this finding is in disagreement with a recent study that did not show any difference in recurrence rate between shortened (≤8 days) and prolonged (>8 days) course of antibiotics among infants with uncomplicated iGBS disease. Overall, the risk of recurrence in uncomplicated iGBS is low, even if antibiotics are used for less than 8 days (35).

How to Prevent Infection of the Asymptomatic Sibling and Recurrence in GBS Disease

Current recommendations of 10 days of intravenous (IV) antibiotics for GBS bacteremia and at least 14 days for meningitis should be adhered to (21). However, following this standard did not prevent early recurrence in several cases in our study. Moreover, and as outlined above, antibiotics in the perinatal area have undisputed costs including an increased susceptibility to sepsis. Thus, empiric antibiotic treatment in this vulnerable phase should be limited to well defined standards of antibiotic stewardship, in particular to early discontinuation if sepsis is ruled out.

The management of twins of iGBS cases has been the subject of several papers and guidelines (15, 18, 21, 36). Current NICE guidelines recommend antibiotic treatment of the other multiple(s) in case of confirmed or suspected EOS, however, no recommendations for LOS are provided (37). If a twin develops GBS EOS, the iGBS risk for the other is up to 40% (25), typically within the next 24h. The short interval in GBS sepsis cases between siblings in our cohort may justify starting antibiotic treatment of the other multiple(s) in case of confirmed or suspected EOS, however, this remains a controversial issue. In any case, a careful clinical observation for the next 24 h seems reasonable (15). In contrast the interval on onset of LOS between siblings is highly variable, which makes parent education important. Routine administration of “prophylactic” antibiotics does not seem justified in LOS, given the missing evidence for a therapeutic effect and the potential costs for the host-microbiome interface (21, 36). Microbiologic investigation of breast milk and, in case of positive culture, antibiotic treatment of the mother seem appropriate in recurrent iGBS or concurrent diseases in multiples, despite lacking evidence. Additionally, probiotics may decrease the incidence of neonatal sepsis in general (38), and experimental models suggest a positive impact on GBS colonization (10, 39). Recommendations are summarized in Table 5.

TABLE 5 | Practical recommendations for investigations and management of the asymptomatic twin in case of invasive GBS disease in a multiple birth or with recurrent course.

| The recommended length of antibiotic treatment is 10 days for bacteremia without focus and 14 days for uncomplicated meningitis. A longer course is recommended when there is a complicated course. |
| When the sibling in a multiple birth has confirmed or suspected invasive GBS disease: |
| • using clinical judgement, consider starting antibiotic treatment of the other multiple(s) in case of confirmed or suspected EOS |
| • apply continuous clinical observation of the asymptomatic twin over min. 24H |
| • immediately start antibiotics with any sign of disease and consider stopping the antibiotics at 36 hours if the blood culture is negative, and the initial clinical suspicion of infection was not strong, and the baby’s clinical condition is reassuring and the levels and trends of biomarkers (GBC, CRP, IL-6) are reassuring |
| • educate the parents about the increased risk for infection in the currently asymptomatic twin and recommend prompt consultation of a doctor in case of any signs or symptoms |

CONCLUSIONS AND OUTLOOK

The dynamics of recurrent GBS infections or concurrent infections in multiples suggest individual patterns of exposure.
and fluctuations in host immunity (Figure 1). As indicated by the low interval of iGBS in affected multiples, GBS can probably clonally – deviate from its usually colonizing traits and become highly invasive, spreading across inter-individual boundaries. This occurs with remarkable frequency, i.e. in a sixth of multiple births in which one infant has iGBS. Identical GBS sero- and sequence types in recurrent cases and concurrently infected multiples may indicate a “streptococcal niche” at colonizing sites, which needs to be demarcated by the immune system and by competing microbes to allow for GBS to become a harmless, metabolically programmed colonizer. The necessary inter-kingdom efforts to achieve lasting coexistence are reflected by the relative long intervals between recurrent iGBS episodes in the affected (preterm) infants, who usually rapidly develop disease once invasively infected. Notably, risk factors for recurrence and simultaneous iGBS in multiples are overlapping, and iGBS in multiples seems to be a risk factor for recurrence. In order to better understand iGBS pathogenesis, it is essential to delineate the risk of empirical antibiotics, as well as the role of antibody-mediated and mucosal cellular immunity in newborn infants in unavoidable contact with GBS and other potential pathogens. It is an intriguing perspective that the improved understanding of host-microbe interface development, including the resolution of the “streptococcal niche”, will allow for the development of designer probiotics capable of improving health in the fragile neonatal period.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The study was approved by the South East Coast– Brighton and Sussex Research Ethics Committee (REC reference: 13/LO/1912; IRAS Project ID: 137959). The detailed methodology has been published. Data collection was approved by the ethics committee of Freiburg University (Nr. 207/20).

REFERENCES

1. Seale AC, Bianchi-Jassir F, Russell NJ, Kohli-Lynch M, Tann CJ, Hall J, et al. Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children. Clin Infect Dis (2017) 65:S200–19. doi: 10.1016/j.clinmicinf.2018-rcpch.284
2. Madrid L, Seale AC, Kohli-Lynch M, Edmond KM, Lawn JE, Heath PT, et al. Infant Group B Streptococcal Disease Incidence and Serotypes Worldwide: Systematic Review and Meta-Analyses. Clin Infect Dis (2017) 65:S160–72. doi: 10.1093/cid/cix566
3. Kohli-Lynch M, Russell NJ, Seale AC, Dangor Z, Tann CJ, Baker CJ, et al. Neurodevelopmental Impairment in Children After Group B Streptococcal Disease Worldwide: Systematic Review and Meta-Analyses. Clin Infect Dis (2017) 65:S190–9. doi: 10.1093/cid/cix663

AUTHOR CONTRIBUTIONS

PH, PTH, KK and MF contributed to conception and design of the study. MF and KK performed analysis of the data and wrote the first draft of the manuscript. KD helped with statistical analysis. PH, PTH, CH, and KLD revised the manuscript. MF, KK, FL, JA, DA, MB, HB, RCA, VC, RCU, LD, ED, AE, RE, ME, JE, RH, CJ, SK, GK, MK, SL, TL, DL, MM, CO’S, DP, AR, CR, SS, ASm, AW, EV and CW were involved in data acquisition. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the Else-Kröner-Fresenius Foundation; the German Ministry of Education and Research (grants 01EO0803, 01GL1746A, 01EK1602A to PH); the German Research Council (grants HE3127/9, HE3127/12, SFB/TRR167 to PH, 413517907 as an IMM-PACT Clinician Scientist fellowship to MP) and Meningitis Now (grant 13.0189). The article processing charge was funded by the Baden-Wuerttemberg Ministry of Science, Research Art and the University of Freiburg in the funding programme Open Access Publishing.

ACKNOWLEDGMENTS

We would like to acknowledge the British Pediatric Surveillance Unit, and all the pediatricians, neonatologists, and microbiologists who have assisted in the study. Additionally, we would like to acknowledge Abdelmajid Djennad and Nick Andrews for assistance with statistical multivariable analysis (Public Health England).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.617925/full#supplementary-material

4. Melin P. Neonatal Group B Streptococcal Disease: From Pathogenesis to Preventive Strategies. Clin Microbial Infect (2011) 17:1294–303. doi: 10.1111/j.1469-0691.2011.03576.x
5. Le Doare K, O’Driscoll M, Turner K, Seedat F, Russell NJ, Seale AC, et al. Intrapartum Antibiotic Chemoprophylaxis Policies for the Prevention of Group B Streptococcal Disease Worldwide: Systematic Review. Clin Infect Dis (2017) 65:S143–51. doi: 10.1093/cid/cix564
6. Nanduri SA, Petit S, Smelser C, Apostol M, Alden NB, Harrison LH, et al. Epidemiology of Invasive Early-Onset and Late-Onset Group B Streptococcal Disease in the United States, 2006 to 2015: Multistate Laboratory and Population-Based Surveillance. JAMA Pediatr (2019) 173:224–33. doi: 10.1001/jamapediatrics.2018.4826
7. Lin FYC, Weisman LE, Trennkle J, Adams K. Prematurity is the Major Risk Factor for Late-Onset Group B Streptococcosis Disease. J Infect Dis (2003) 188:267–71. doi: 10.1086/376457
